
Surgical Oncologist & Clinical Epidemiologist @CedarsSinai @DeptSurgeryCS | Soft Tissue Sarcoma & GI Malignancies | 🇨🇦
Joined October 2010
- Tweets462
- Following707
- Followers1.2K
- Likes1.5K
Fahima Dossa, MD PhD retweeted
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre RCT phase III thelancet.com/journals/lanon…
Fahima Dossa, MD PhD retweeted
🎙️ Proud of our own former @DukeSurgRes Resident, Dr. Nellie Farrow (now @EmoryMedicine)! Check out her new @SocSurgOnc micro-learning on MSLT-3 & melanoma paradigm shifts with Dr. Mark Faries of Cedar Sinai. #SurgOnc
learn.surgonc.org/courses/23…
Fahima Dossa, MD PhD retweeted
Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? Co-authored by @fdossa.
Read the full article. bit.ly/4vuPmU8
SARC041: confirms clinical activity of abemaciclib for pts with advanced dediff liposarcoma ✅
👏🏽 to Mark Dickson @MSKSarcoma on this work and Paolo Casali @casali_pg @IstTumori for an excellent discussion
Open❔role in resectable disease
#ASCO26
Fahima Dossa, MD PhD retweeted
A much needed breakthrough for our pts with #PDAC 👏👏. Glad to see amongst investigators for this important study, our fearless #GImedonc leader @DrHendifar as an author in the @NEJM manuscript
@OncoAlert @DrArsenOsipov @AGangiMD @_BrainyMD_ @CFerroneMD @fdossa @CedarsSinaiMed
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Congratulations to @DrDrFoster of @Stanford University, recipient of the SSAT Career Development Award! 🎉 Dr. Foster’s work reflects the innovation and dedication that continue to advance the field of digestive diseases.
#Surgery #AcademicMedicine #Research #StanfordUniversity
Fahima Dossa, MD PhD retweeted
This is a great read on watch & wait in rectal cancer.
B/c patients with local regrowth after WW have higher rates of distant mets, there has been an intuitive fear that regrowth is causal (i.e delaying TME permits metastatic seeding hence WW risky).
The authors here argue (and I agree) that regrowth/metastases are manifestations of intrinsic aggressive tumor biology because:
1) no difference in time to surgery in patients w pCR/regrowth who developed mets vs. those who didn't (if delay were causal, would expect longer delay in patients who developed M1).
2) in OPRA secondary analysis, patients with cCR underwent least surgery/longest observation while those with incomplete response had surgery most frequently/immediately. But outcomes still tracked with response phenotype not timing of surgery (i.e. cCR did best).
3) tumor response itself is prognostic (i.e. even when all pts undergo TME, more regression after neoadjuvant therapy --> better DFS/DM).
4) modern tumor evolution data suggest metastatic spread mostly happens early.
5) chemo/radioresistance appears to be linked to metastatic potential (i.e. regrowth is a marker of aggressive biology not the mechanism itself).
IMO a persuasive argument against hypothesis that regrowth seeds metastasis, but rather biology=dominant driver. @OncoAlert
Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Thrilled to finally see this out - 🚨#Sarculator bayesian update for more refined risk estimates in extremity soft tissue sarcoma
App📱update and @LancetOncology pub: sciencedirect.com/science/ar…
Phenomenal work @DCalleMD, Gabriele Tine, et al. ! 👏🏽👏🏽
The #Sarculator app update is now live!
This comes together with our @TheLancetOncol paper introducing #BayeSarc, a Bayesian sequential learning approach to refine prognostication in extremity soft tissue #sarcoma.
Paper: sciencedirect.com/science/ar…
App: apps.apple.com/it/app/sarcul…
With ⤴️use of W&W for rectal cancer, how can we safely 🫸the limits? Is there a role for W&W in pts with *near* complete response or does this risk distant disease?
More on the📊 and our recommendations for safe W&W practices: ascopubs.org/doi/10.1200/JCO…
@JCO_ASCO @DrGarciaAguilar
New RCT data 📈 supporting the efficacy of Doxil for progressing desmoid tumors. Now 3 options supported by level 1 data - but how to choose? 🧐
👀 editorial in @CCR_AACR with @SilviaStacchia and @alegronchi
aacrjournals.org/clincancerr…
Congrats @seacm! 👏🏽 👏🏽
Celebrating @seacm on receiving the AHPBA Research Development Grant. This is the impact we strive for: advancing science, elevating care and leading the way.
uab.edu/medicine/news/surger…
Fahima Dossa, MD PhD retweeted
Great way to cap off #colorectalcancer awareness month hosting our @CSCancerCenter #CRC research social w/Dr. Alessio Pigazzi @EdwinPosadasMD for a productive exchange of ideas, networking & future collabs w/PhDs & MDs in #CRC research @AGangiMD @fdossa @SGrivennikov @SekiEki
Building on terrific #SSO2026 and @TARPSWG meetings, check out our📄on current dx & tx strategies for soft tissue sarcoma @BjsOpen, including recent technical advances and multiD approaches
@ctosociety @SocSurgOnc @ESSOnews @_CSSO @FioreDoc @alegronchi
academic.oup.com/bjsopen/art…
Fahima Dossa, MD PhD retweeted
ctDNA🩸: game-changer or expensive crystal ball?🔮
💡What surgeons should do with ctDNA in CRC, gastric & cholangiocarcinoma at #SSO2026 with @ColinCourtMD @fdossa @FlavioRochaMD & wrap-up by @rachnatshroff
Join us in Phoenix👉🏻 tinyurl.com/55upkjsr
Fahima Dossa, MD PhD retweeted
Sarcoma family dinner 💛thank you @SilviaStacchia and @alegronchi for welcoming us into your home, workplace and international sarcoma family! @TARPSWG @ctosociety @UofTSurgOnc
Thanks so much for the invite! Really enjoyed the discussion that followed about the future of #clinicaltrials in oncology - improving design and interpretation!
When p > 0.05 is not the end of the conversation. Fantastic Grand Round by @fdossa on how statistical misunderstandings can shape (and misshape) treatment decisions. A must-hear for clinicians. #sarcoma #clinicaltrials #statistics #oncology #surgery
Fahima Dossa, MD PhD retweeted
Kicking off #CTOS2024 with @TARPSWG this morning. @FioreDoc leading the discussion on 🌎 collaboration to standardize RPS terminology 👏👏 #CTOSTweeTOS
Fahima Dossa, MD PhD retweeted
TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24
Fahima Dossa, MD PhD retweeted
It’s out! This guideline @JAMAOnc #desmoid reflects our multidisciplinary global collaboration, highlights new treatment strategies &importance of quality of life. Thanks Bernd Kasper, @alegronchi, pts, all.
Current Management of Desmoid Tumors: A Review. pubmed.ncbi.nlm.nih.gov/3890…



































